Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular
Kuang-Hua Chen1, Shihui Liu2, Clinton E Leysath1
1From the Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Bethesda, Maryland 20892-3202 and.
Abstract:
The protective antigen (PA) moiety of anthrax toxin binds to cellular receptors and mediates the translocation of the two enzymatic moieties of the toxin to the cytosol. Two PA receptors are known, with capillary morphogenesis protein 2 (CMG2) being the more important for pathogenesis and tumor endothelial marker 8 (TEM8) playing a minor role. The C-terminal PA domain 4 (PAD4) has extensive interactions with the receptors and is required for binding. Our previous study identified PAD4 variants having enhanced TEM8 binding specificity. To obtain PA variants that selectively bind to CMG2, here we performed phage display selections using magnetic beads having bound CMG2. We found that PA residue isoleucine 656 plays a critical role in PA binding to TEM8 but has a much lesser effect on PA binding to CMG2. We further characterized the role of residue 656 in distinguishing PA binding to CMG2 versus TEM8 by substituting it with the other 19 amino acids. Of the resulting variants, PA I656Q and PA I656V had significantly reduced activity on TEM8-expressing CHO cells but maintained their activity on CMG2-expressing CHO cells. The preference of these PA mutants for CMG2 over TEM8 was further demonstrated using mouse embryonic fibroblast cells and mice deficient in the CMG2 and/or the TEM8 receptors. The structural basis of the alterations in the receptor binding activities of these mutants is also discussed.
Insights
Researchers engineered anthrax toxin
Area of Science:
- Microbiology
- Molecular Biology
- Toxicology
Background:
- Anthrax toxin's protective antigen (PA) binds cellular receptors to deliver enzymatic moieties.
- Capillary morphogenesis protein 2 (CMG2) and tumor endothelial marker 8 (TEM8) are known PA receptors.
- PA domain 4 (PAD4) mediates PA receptor interactions.
Purpose of the Study:
- To develop PA variants with selective binding to CMG2.
- To investigate the role of PA residue isoleucine 656 in receptor binding specificity.
Main Methods:
- Phage display selections using CMG2-bound magnetic beads.
- Site-directed mutagenesis of PA residue 656.
- Functional assays using cell lines and receptor-deficient mice.
Main Results:
- PA residue isoleucine 656 is critical for TEM8 binding but less so for CMG2 binding.
- PA variants I656Q and I656V showed reduced TEM8 activity but retained CMG2 activity.
- Mutant preference for CMG2 over TEM8 was confirmed in cellular and animal models.
Conclusions:
- PA residue 656 is a key determinant for distinguishing CMG2 and TEM8 binding.
- Engineered PA variants demonstrate selective CMG2 binding, offering potential for targeted applications.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
